Stockscreener 앱 받기
27.84
0.40%
0.11
시간 외 거래:
27.84
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics Hits Day High with Strong 7.14% Intraday Surge - Markets Mojo
Setup Watch: What are the future prospects of Viridian Therapeutics IncWeekly Investment Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Dow Update: Will Viridian Therapeutics Inc outperform its industry peers2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc. - MarketBeat
How Viridian Therapeutics Inc. stock responds to policy changesMarket Growth Report & Advanced Technical Analysis Signals - mfd.ru
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Earnings Beat: Is Viridian Therapeutics Inc subject to activist investor interestGap Up & Low Risk Investment Opportunities - baoquankhu1.vn
VRDN: Wedbush Reiterates 'Outperform' Rating with $44 Target | V - GuruFocus
Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront - MSN
(VRDN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RBC Capital lowers its price target on Viridian Therapeutics, Inc. (VRDN) to $42 and maintains an outperform rating - MSN
Viridian Therapeutics (VRDN) CFO amends Form 4 for tax-share disposal - Stock Titan
Viridian (VRDN) COO adjusts 3,048-share tax withholding in Form 4 amendment - Stock Titan
Viridian Therapeutics (VRDN) legal chief updates tax share disposition - Stock Titan
Viridian Therapeutics (NASDAQ: VRDN) CEO amends Form 4 tax sale - Stock Titan
Analyst Upgrade: Can Viridian Therapeutics Inc be the next market leader2026 Weekly Recap & Consistent Profit Alerts - baoquankhu1.vn
Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion By Investing.com - Investing.com Canada
Published on: 2026-03-07 18:48:40 - baoquankhu1.vn
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Volume Recap: Can Viridian Therapeutics Inc withstand a market correctionJuly 2025 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Can Viridian Therapeutics Inc stock double in the next yearEarnings Beat & Community Trade Idea Sharing Platform - baoquankhu1.vn
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating - Finviz
Vanguard Group Inc. Has $93.48 Million Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (VRDN) CEO awarded 559,600 stock options and new RSUs - Stock Titan
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia
[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan
VRDN (NASDAQ: VRDN) Form 144: proposed sale of 1,675 vested shares - Stock Titan
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC - MarketBeat
Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Biotech Powerhouse with 38% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Valuation After Wider Q4 Loss And Ongoing Thyroid Eye Disease Regulatory Reviews - simplywall.st
Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration - Sahm
What analyst consensus says on Viridian Therapeutics Inc. stockRisk Management & Free Growth Oriented Trading Recommendations - mfd.ru
How (VRDN) Movements Inform Risk Allocation Models - Stock Traders Daily
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics (VRDN) Analyst Maintains Rating; Adjusts P - GuruFocus
RBC Adjusts Price Target on Viridian Therapeutics to $42 From $45, Maintains Outperform Rating - marketscreener.com
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders - Yahoo Finance
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO) - The Globe and Mail
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026 - Meyka
VRDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
Stifel reiterates Viridian Therapeutic stock rating on BLA review By Investing.com - Investing.com Canada
Jefferies raises Viridian Therapeutic stock price target on trial progress By Investing.com - Investing.com Canada
Wedbush Cuts Viridian Therapeutics Price Target to $44 From $47, Maintains Outperform Rating - marketscreener.com
Evercore ISI reiterates Viridian Therapeutic stock rating on data conviction By Investing.com - Investing.com Canada
Viridian Therapeutics earnings beat by $0.64, revenue topped estimates - Investing.com
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Viridian Therapeutics earnings missed by $0.10, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Q4 revenue misses analyst expectations - TradingView
Viridian Therapeutics Reports Q4 and Full Year 2025 Financial Results - TradingView
TED drug veligrotug nears FDA decision as Viridian (NASDAQ: VRDN) ramps spend - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):